IL2hoidoissa
IL2hoidoissa, or interleukin-2 therapy, refers to medical treatments that use the cytokine interleukin-2 (IL-2) to stimulate immune responses against disease. In oncology, high-dose IL-2 therapy has been used to treat metastatic renal cell carcinoma and metastatic melanoma, with the goal of activating T cells and natural killer cells to attack tumor cells. The mechanism involves promoting proliferation and activation of cytotoxic immune cells, but high-dose regimens can cause severe toxicity, including capillary leak syndrome, hypotension, renal impairment, and organ dysfunction. Because of the risk profile, high-dose IL-2 is administered in specialized inpatient settings with intensive hemodynamic monitoring.
Low-dose IL-2 regimens have also been explored, aiming to modulate the immune system with less toxicity. These
Indications and use: IL-2 therapies were historically standard care for certain metastatic cancers, particularly renal cell
Administration: High-dose IL-2 is typically given as a course of intravenous infusions every several hours over
Outcomes and side effects: Response rates are modest, and complete responses are rare but can be durable
History: IL-2 therapy received regulatory approval in the 1990s and represents an early form of cancer immunotherapy,